Delta Lloyd notify of 4.96% shareholding in Galapagos
January 21 2015 - 12:56PM
Mechelen,
Belgium; 21 January 2015 - Galapagos NV (Euronext: GLPG) received a
transparency notification from Delta Lloyd N.V.
Pursuant to Belgian transparency
legislation[1], Galapagos
received a transparency notification on 16 January 2015 from Delta
Lloyd N.V. Delta Lloyd notified that on 14 January 2015
entities under their control held 1,503,630 shares, representing
4.96% of the current 30,299,129 outstanding Galapagos shares.
This represents a reduction of Delta Lloyd's participation
compared to the previous notification of 2,954,890 shares owned by
Delta Lloyd Asset Management N.V. in September 2013.
About
Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising three Phase 2
programs, two Phase 1 studies, five pre-clinical, and 25 discovery
small-molecule and antibody programs in cystic fibrosis,
inflammation, antibiotics, metabolic disease, and other
indications. In the field of inflammation, AbbVie and
Galapagos signed an agreement for the development and
commercialization of GLPG0634. GLPG0634 is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos has another selective JAK1 inhibitor,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG1205, a first-in-class inhibitor of GPR84, is
currently being tested in a Phase 2 Proof-of-Concept study in
ulcerative colitis patients. GLPG1690 is a first-in-class
compound that targets pulmonary diseases and is currently in a
Phase 1 study. AbbVie and Galapagos signed an agreement in
cystic fibrosis to develop and commercialize molecules that address
mutations in the CFTR gene. Potentiator GLPG1837 started
Phase 1 last month, and corrector GLPG2222 is at the pre-clinical
candidate stage. The Galapagos Group, including
fee-for-service subsidiary Fidelta, has around 400 employees,
operating from its Mechelen, Belgium headquarters and facilities in
The Netherlands, France, and Croatia. Further information at:
www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications &
IR
Tel: +31 6 2291 6240
ir@glpg.com
This release may
contain forward-looking statements, including, without limitation,
statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"could," "stands to," and "continues," as well as similar
expressions. Such forward-looking statements may involve known and
unknown risks, uncertainties and other factors which might cause
the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied by
such forward-looking statements. Given these uncertainties, the
reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements speak
only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change
in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
[1]
Belgian Act of 2 May 2007 on the disclosure of major shareholdings
in issuers whose shares are admitted to trading on a regulated
market)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
HUG#1888590
Galapagos (LSE:GLPG)
Historical Stock Chart
From May 2024 to Jun 2024
Galapagos (LSE:GLPG)
Historical Stock Chart
From Jun 2023 to Jun 2024